Ophthalmology
Eye diseases cause very high socioeconomic costs and substantially diminished quality of life for those affected. Karolinska Development’s ophthalmology company, Clanotech, is developing treatments for macular degeneration and retinopathy associated with diabetes. Both of these diseases are characterized by pathological ocular neovascularization, which is counteracted by the company’s therapeutic concept.
| Ophthalmology | Concept Development | Lead Discovery | Lead Optimization | Preclinical Development | Phase I | Phase II | Phase III | Launch | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
||||||||||||||||
Clanotech ABClanotech is developing small molecules for alpha5beta1-integrin inhibition for treatment of diseases of the eye. www.clanotech.se |
|
|